Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

otocol Assessment (SPA) agreement with the FDA, the Phase 3 clinical program for Zerenex consists of two clinical studies, the completed short-term study, and a long-term safety and efficacy study that is currently ongoing.

About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Pearl's Premium Ultra ... in drought tolerant grass seed this week with the ... The announcement coincides with the fact that it is ... as many believe. , As of the date ... favorable reviews by industry experts and the media including: ...
(Date:9/22/2014)... components developed by researchers at the USC Viterbi ... build a 3-D microfluidic system quickly and cheaply ... , Microfluidic systems are used in many ... manipulate small volumes of fluids for use in ... detection, clinical diagnostic testing, and synthetic chemistry. Traditionally, ...
(Date:9/22/2014)... have generated a new star-shaped molecule made up of interlocking ... created. , Known as a ,Star of David, ... a quarter of a century and the team,s findings are ... Consisting of two molecular triangles, entwined about each other three ... each triangle is 114 atoms in length around the ...
(Date:9/22/2014)... Washington D.C. (PRWEB) September 22, 2014 ... and Georgetown President John DeGioia on Friday renewed ... understanding for an additional five years to expand ... security, biosecurity, nonproliferation and global climate, energy and ... expansion of an MOU originally signed in December ...
Breaking Biology Technology:Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2
... bus and train tickets and access health and other public ... card or passport, thanks to technology developed by this European ... or filling out forms, however patiently we suffer them. Electronic ... to offices and waiting for our identities and details to ...
... , FLEMINGTON, N.J. , June 24 Beardsworth ... M.D. as the company,s Scientific Advisor, Oncology and Robert W. Malone ... , , ... of oncology,s respected research leaders with over 20 years of clinical research ...
... BERLIN , June 25, 2010 Industrial ... percent per year through 2020. Germany ,has already ... nascent industry, making it an ideal site for,companies looking ... & Invest will be on hand at this year,s ...
Cached Biology Technology:Really smart card project scoops EUREKA 2010 Innovation Award 2Really smart card project scoops EUREKA 2010 Innovation Award 3Really smart card project scoops EUREKA 2010 Innovation Award 4Alison Martin, MD and Robert W. Malone, MD Join Beardsworth 2Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 2Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 3
(Date:9/22/2014)... 2014) Additive manufacturing (AM), or 3D printing, ... of complex-shaped metal components strong enough for structural ... and distortions, as well as quality standards to ... with the technology. Engineers at the University of ... develop enhanced modeling and simulation (M&S) technology and ...
(Date:9/22/2014)... larger areas of sea ice melt in the summer and ... is thinner and more reduced. As the Arctic summers are ... because reduced sea ice in the Arctic will remove less ... results are representative, then sea ice plays a greater role ... future global CO2 budgets", says Dorte Haubjerg Sgaard, PhD Fellow, ...
(Date:9/21/2014)... Mothers of children with autism are significantly less likely ... pregnancies than the mothers of children who are developing ... MIND Institute has found. , Low iron intake was ... the child if the mother was 35 or older ... she suffered from metabolic conditions such as obesity hypertension ...
Breaking Biology News(10 mins):Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3Arctic sea ice helps remove CO2 from the atmosphere 2Mothers of children with autism less likely to have taken iron supplements 2
... afternoon and you have no appetite and don,t want to do ... researchers from the ARC Centre of Excellence for Coral Reef Studies ... some large reef fish feel the same way. Researcher Dr ... activities necessary for survival, including hunting for food and finding mates. ...
... have shown that Fructus corni has a protective ... and antiseptic properties. 5-hydroxymethylfurfural, a compound extracted from ... hippocampal neurons damaged by H2O2. Prof. Mingyan Wang ... for the first time, used cytobiological and molecular ...
... have been awarded the distinction of Fellow by the American ... to this rank because of their efforts toward advancing science ... of all 388 AAAS fellows for 2013 are announced in ... four Smithsonian honorees are: Helen James, research ...
Cached Biology News:Reef fish find it's too hot to swim 2Smithsonian scientists honored as AAAS Fellows 2
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... Protein Kit is a simple and convenient method ... The kit has been optimized for use with ... used for any fungus species that is susceptible ... procedure effectively generates spheroplasts of yeast cells that ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Biology Products: